Rapid diagnostics of actionable mutations in acute myeloid leukemia using amplicon nanopore sequencing
This study presents a clinically implemented Oxford Nanopore amplicon sequencing assay that achieves rapid (32-hour), highly accurate (98.4–100% sensitivity/specificity) detection and phasing of actionable mutations in acute myeloid leukemia, including FLT3-ITDs and TP53 variants, to streamline risk stratification and treatment selection.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a person is diagnosed with acute myeloid leukemia, a cancer of the blood and bone marrow, the clock starts ticking immediately. This disease is not a single condition but a collection of disorders that behave very differently from one patient to the next. The key to survival lies in understanding the specific genetic mistakes driving the cancer in each individual. Doctors look for changes in the DNA of the leukemia cells, such as broken genes or duplicated sections, because these details determine how aggressive the disease is and which medicines will work best. For years, finding these clues has been a slow process. Standard laboratory tests often require running multiple different machines and waiting for samples to be grouped together in batches, which can take several days. In a rapidly changing disease like leukemia, waiting three to five days for a genetic report can delay life-saving treatment decisions.
Researchers at Uppsala University in Sweden, working with colleagues from hospitals in France, have developed a new way to speed up this process. They created a test that uses a technology called long-read sequencing to read the genetic code of leukemia cells much faster than before. Instead of breaking the DNA into tiny pieces and trying to reassemble them like a puzzle, this method reads long, continuous stretches of the genetic code. The team focused on five specific genes known to be critical in leukemia: NPM1, FLT3, IDH1, IDH2, and TP53. By designing a test that targets only these genes, they aimed to provide a complete genetic picture of a patient's leukemia in less than two days, allowing doctors to start the right therapy sooner.
The team tested their new approach in three stages to ensure it was accurate and reliable. First, they looked back at samples from 36 patients whose genetic mutations were already known from previous tests. They ran these samples through their new system, which uses a device called a MinION sequencer. This machine is small enough to sit on a desk and can read DNA strands as they pass through tiny pores. The researchers found that the new test detected 63 out of 64 known mutations, a success rate of nearly 98 percent. It successfully identified complex genetic errors, including a type of mutation in the FLT3 gene that is notoriously difficult to spot with older methods. The test also showed it could read the genetic code with enough clarity to tell if two different mutations were on the same strand of DNA or on opposite strands, a detail that is crucial for understanding how the cancer behaves but is often missed by standard tests.
Next, the researchers focused specifically on the TP53 gene, which is often mutated in difficult-to-treat cases of leukemia. They analyzed samples from 18 patients who carried multiple mutations in this gene. The new test found every single one of these mutations and successfully determined their arrangement on the DNA strands. This ability to "phase" the mutations, or figure out which ones travel together on the same piece of DNA, confirmed that the technology could handle the most complex genetic scenarios. Finally, the team put the test to work in a real-world clinical setting. They took 26 new patients who had just been diagnosed with leukemia and ran their samples through the new system alongside the standard hospital tests. The results were perfect: the new test found every mutation that the standard tests found, and it did not report any false errors. The entire process, from the moment the sample arrived in the lab to the final report, took an average of about 32 hours.
One of the most significant advantages of this new method is its flexibility. Traditional genetic tests often require a laboratory to wait until they have enough samples to fill a machine, which can cause delays. This new system can process a single patient's sample immediately, without waiting for others. The researchers also found that the flow cell, the small cartridge that holds the DNA during sequencing, could be washed and reused up to five times without losing quality. This reuse keeps the cost of the test low, making it comparable to the price of the standard tests currently used for just one type of mutation. While the test is highly accurate, the researchers noted a small limitation: it might miss very rare mutations that appear in less than one percent of the cells. However, for the vast majority of cases, this rapid test provides a clear and immediate answer.
The study demonstrates that it is possible to bring advanced genetic analysis out of the research lab and into the daily routine of a hospital. By delivering actionable genetic information within two days, this approach allows doctors to make informed decisions about treatment much faster than before. The researchers have already begun using this method in their own institution and are considering how it could be adopted more widely. In a field where time is often the most critical factor, this technology offers a way to see the genetic landscape of leukemia clearly and quickly, ensuring that patients receive the right care at the right time.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.